Brief: PharmAbcine Reports Positive Results for Its Novel TIE2-Activating Antibody in GLP Toxicology Study
26/04/2022 13:43
April 26 (Reuters) - PharmAbcine Inc 208340.KQ :
* PHARMABCINE ANNOUNCES POSITIVE RESULTS FOR ITS NOVEL
TIE2-ACTIVATING ANTIBODY IN GLP TOXICOLOGY STUDY
Source text for Eikon: ID:nPn6JZ3Zla
Further company coverage: 208340.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PharmAbcine
See all newsBrief: Pharmabcine Announces Safety Approval For 1st dose Cohort In Phase 1A/B Clinical Trial Of Pmc-309
Brief: Pharmabcine To Conduct Capital Increase Of 26 Billion Won For Operational Funds
Brief: Pharmabcine To Conduct Capital Increase Of 3.7 Billion Won For Operational Funds
Brief: Pharmabcine To Conduct Capital Increase Of 4.7 Billion Won For Operational Funds
Brief: PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration